Please ensure Javascript is enabled for purposes of website accessibility

Why Fresenius Medical Care AG & Co. KGaA Is Tanking Today

By Brian Feroldi - Updated Oct 17, 2018 at 11:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares tumble after management dials back guidance. Here's what investors need to know.

What happened

After management poured cold water on its financial outlook, shares of Fresenius Medical Care (FMS -0.22%), the world's largest provider of dialysis products and services, plunged 17% as of 10:55 a.m. EDT on Wednesday.

So what

Here's an overview of the financial guidance that management shared with investors today.

  • Fresenius Medical Care now expects its fiscal-year 2018 sales to grow between 2% and 3%. That's below its prior guidance that called for growth of 5% to 7%.
  • Net income is expected to grow by 11% to 12% in constant -currency terms. That's also below its previous call for growth of 13% to 15%. Adjusted net income is only expected to grow 2% to 3% in currency-neutral terms. That's also shy of its prior call for 7% to 9% growth. 
Businessman with coins falling through his hands.

Image source: Getty Images.

Given the disappointing news, it isn't hard to figure out why shares are getting whacked today.

Now what

Fresenius' investors have been patiently waiting for more than a year for the company's $2 billion deal to acquire NxStage Medical (NXTM) to go through. Since the closing of the acquisition might have helped the company to meet its financial targets, investors should hope that the deal gets finalized soon.

The latest update is that the merger agreement closing date has been extended to November of 2018. That should provide the company with enough time to complete the deal. However, should something go awry, Fresenius would owe NxStage Medical a $60 million acquisition termination fee, so the pressure is on for the company to execute.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends NxStage Medical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nxstage Medical, Inc. Stock Quote
Nxstage Medical, Inc.
NXTM
Fresenius Medical Care AG & Co. KGaA Stock Quote
Fresenius Medical Care AG & Co. KGaA
FMS
$18.12 (-0.22%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.